Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
NCT ID: NCT03497845
Last Updated: 2020-07-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
720 participants
INTERVENTIONAL
2018-03-15
2019-11-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study is designed to evaluate the safety and immunogenicity of vaccination strategies with homologous or antigenically distant heterologous H5 influenza virus vaccines administered with AS03 or MF59 adjuvant.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
H5N1 Mix and Match With AS03
NCT01317758
Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine
NCT03300050
Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals
NCT03816878
H5N1 Vaccination With and Without AS03: Systems Biology Analysis
NCT01573312
Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)
NCT00812019
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
a VN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant
Single dose of Vietnam (VN) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/Washington (WA) (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
VN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
b IN with AS03 Adjuvant, then gf/WA with AS03 Adjuvant
Single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
IN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
c dk/BANG with AS03 Adjuvant, then gf/WA with AS03 Adjuvant
Single dose of dk/Bangladesh (BANG) (H5N1) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
dk/BANG
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
d gf/WA with AS03 Adjuvant, then IN with AS03 Adjuvant
Single dose of gf/WA (H5N8) vaccine with AS03 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with AS03 Adjuvant (Dose 2 = Day 22).
IN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
e dk/BANG with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant
Two doses of dk/BANG (H5N1) vaccine with AS03 Adjuvant (Dose1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/Qinghai Lake(QL) (H5N1) vaccine with AS03 Adjuvant (Day 142).
dk/BANG
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
f gf/WA with AS03 Adjuvant, then bhg/QL with AS03 Adjuvant
Two doses of gf/WA (H5N3) vaccine with AS03 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with AS03 Adjuvant (Day 142)
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
g VN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant
Single dose of VN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
VN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
h IN with MF59 Adjuvant, then gf/WA with MF59 Adjuvant
Single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
IN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
i dk/BANG with MF59 Adjuvant, then gf/WA with MF59 Adjuvant
Single dose of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
dk/BANG
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
j gf/WA with MF59 Adjuvant, then IN with MF59 Adjuvant
Single dose of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1), followed by single dose of IN (H5N1) vaccine with MF59 Adjuvant (Dose 2 = Day 22).
IN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
k dk/BANG with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant
Two doses of dk/BANG (H5N1) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22); followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
dk/BANG
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
l gf/WA with MF59 Adjuvant, then bhg/QL with MF59 Adjuvant
Two doses of gf/WA (H5N8) vaccine with MF59 Adjuvant (Dose 1 = Day 1; Dose 2 = Day 22), followed by single dose of bhg/QL (H5N1) vaccine with MF59 Adjuvant (Day 142).
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
IN
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
dk/BANG
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
gf/WA
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
bhg/QL
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
AS03 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
MF59 adjuvant
0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Will avoid nonstudy vaccinations until 21 days after the last vaccination.
3. Provides written informed consent prior to the initiation of any study-related procedures.
4. Has a stable health status, as established by physical examination, vital sign measurements, and medical history.
5. Has access to a consistent and reliable means of telephone contact, which may be in the home, workplace, or by personal mobile electronic device.
6. Is able to understand and comply with planned study procedures.
7. Lives a reasonable distance from the site to be able to travel to and from the site for follow-up visits and agrees to go to the site for evaluation in the case of an adverse event.
8. Agrees to stay in contact with the site for the duration of the study, has no current plans to move from the study area, and provides updated contact information as necessary.
Exclusion Criteria
2. A woman who has a positive urine pregnancy test prior to vaccination in this study or a woman who is breastfeeding.
3. A female of childbearing potential (a) who refuses to use an acceptable method of birth control (b) from Day 1 (first vaccination) to end-of-study visit and, if sexually active, who has not used a reliable birth control method for at least 2 months prior to Day 1 (first vaccination).
1. Female of childbearing potential is defined as post-onset menarche and premenopausal female capable of becoming pregnant. This does not include females who meet any of the following conditions: menopausal \>1 year, tubal ligation \>1 year, bilateral salpingo-oophorectomy, or hysterectomy.
2. Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and, when applicable, in accordance with the product label, for example: abstinence from penile-vaginal intercourse; oral contraceptives, either combined or progestogen alone; injectable progestogen; implants of etonogestrel or levonorgestrel; estrogenic vaginal ring; percutaneous contraceptive patches; intrauterine device or intrauterine system; male partner sterilization at least 6 months prior to the female Day 1 (first vaccination), and this male is the sole partner for that subject (The information on the male sterility can come from the site personnel's review of the subject's medical records or interview with the subject on her medical history); male condom combined with a vaginal spermicide (foam, gel, film, cream, or suppository); male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
4. Is immunosuppressed as a result of an underlying illness or treatment, or anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36 months prior to Day 1 (first vaccination).
5. Has an active neoplastic disease or a history of any hematologic malignancy. A subject with superficial skin cancer who does not require intervention other than local excision is not excluded.
6. Has long-term use (≥14 consecutive days) of glucocorticoids including oral or parenteral prednisone or equivalent (\>20 mg total dose per day) or high-dose inhaled steroids (\>800 mcg/day of beclomethasone dipropionate or equivalent) within 1 month prior to screening. (Low-dose \[≤800 mcg/day of beclomethasone dipropionate or equivalent\] inhaled and topical steroids are allowed).
7. Has a diagnosis of schizophrenia, bipolar disease, or other major psychiatric diagnosis.
8. Has been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others, within the past 10 years.
9. Has a neurological or psychiatric diagnosis, which, although stable, is judged by the investigator to render the potential subject unable or unlikely to comply with the protocol or to provide accurate safety reports.
10. Has received immunoglobulin or other blood product (with the exception of Rho\[D\] immune globulin) within the 3 months prior to Day 1 (first vaccination).
11. Has received any live vaccine within 4 weeks or inactivated vaccines within 2 weeks prior to Day 1 (first vaccination). This includes seasonal influenza vaccines.
12. Has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. This includes potentially immune-mediated medical conditions such as Guillain-Barré syndrome, narcolepsy, current or history of autoimmune or chronic inflammatory disease.
13. Has a first-degree relative with narcolepsy.
14. Has an acute illness, including body temperature greater than 100.4°F, at screening, immediately prior to each vaccination or, per subject report, within 3 days prior to each vaccination. Subjects with an acute illness can be rescheduled for a vaccination as long as the vaccination visit is within the visit window. Note that subjects may return for randomization following resolution of the acute illness as long as recruitment remains open and subjects are within 14 days of signing consent.
15. Has a Grade 2 or greater (by US Food and Drug Administration toxicity grade) safety laboratory value at screening.
16. Has received an experimental agent (vaccine, biologic, device, blood product, or medication) within 1 month prior to Day 1 (first vaccination) in this study or plans receipt of an experimental agent during the study period.
17. Is participating or plans to participate in another interventional clinical study (either active or follow-up phase) during the study period.
18. Has received an influenza H5 vaccine in the past or has a history of H5 influenza infection prior to enrollment.
19. Has known human immunodeficiency virus, hepatitis B, or hepatitis C infection.
20. Has a history of alcohol or drug abuse within 5 years prior to Day 1 (first vaccination).
21. Has a body mass index \>35 kg/m2.
22. Has any condition that would, in the opinion of the investigator, place him or her at an unacceptable risk of injury or render him or her unable to meet the requirements of the protocol (including site of injection reactogenicity assessments).
23. Is a first-degree relative of any person working on this study: site or sponsor.
18 Years
49 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biomedical Advanced Research and Development Authority
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Optimal Research
San Diego, California, United States
Optimal Research
Peoria, Illinois, United States
Johnson County Clin-Trials
Lenexa, Kansas, United States
Central Kentucky Research Associates Inc
Lexington, Kentucky, United States
Optimal Research
Rockville, Maryland, United States
Rochester Clinical Research, Inc
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BP-I-16-005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.